Dharmendra Singh Email & Phone Number

Newark, Ca, Us

South San Francisco, California, Us

• Participating in 2 clinical studies focused on oral, small molecule GLP-1 receptor agonist drug for treating Type 2 Diabetes Mellitus (T2DM) and Obesity (Phase I and II studies).• Work efficiently with cross-functional teams including, CROs, vendors, quality assurance (QA), clinical outsourcing, and finance to meet clinical trial objectives.• Supporting study leads with document review and management during the start-up, enrollment, maintenance, and closeout activities. • Reviewed trial-related documents including, ICFs, SOPs, monitoring and oversight reports, site source data templates, eCRF templates, vendor contracts, site feasibility questionnaires, site qualification visit (SQV) reports, site selection documents, etc. • Maintaining Trial Master File (TMF) for Phase I and Phase II clinical trials and helping with periodic eTMF QC.• Worked on the Rave Electronic Data Capture (EDC) system (iMedidata) to review subject visit information.• Supervised study-specific SOP training for the team to ensure compliance with GDP regulatory policies. • Created exemplary tracker spreadsheets to track essential clinical trial documents, subject critical data, master vendor lists, study site selection, site qualification visits, etc.• Presenting work to the team, preparing meeting minutes, and working efficiently to prioritize tasks to meet critical trial deadlines.

• Advised on cell-based assay development including cell line selection, cell toxicity/ proliferation assays, and drug screening.• Advised the company management on business and product development,

Newark, California, Us

• Led and managed multiple oncology pre-clinical drug discovery projects (small molecule), prioritizing complex experimental work, assay development and data analysis.• Served as a laboratory operation manager, managing vendors, and maintaining resources to execute and deliver projects on time.• Developed in vitro biochemical and cell-based assays to identify and characterize novel small molecule inhibitors against multiple oncogenic targets.• Worked with the finance team to manage project budgets, resulting in improved efficiency in project execution. • Kept track of scientific literature and protocols for developing novel assays, and presented the data internally and externally. • Worked with the team to customize the ELN/ data acquisition platform.• Experience working with MS Word, Excel, PowerPoint, and Outlook.• Successfully managed CROs to complete the projects efficiently on time.• Trained and supervised RA and summer intern.The position was impacted by layoff due to the failure of a Phase III clinical trial.

Fremont, California, Us

• Successfully managed and executed multiple bioassay development work to measure CBC and CMP parameters. • Worked within a highly collaborative cross-functional team environment involving biologists, engineers, and data analysts to execute the projects.• Extensively used advanced MS Excel and GraphPad Prism functions for data analysis.• Managed various vendors, external collaborations.• Trained scientists and Research Associates.

Boston, Massachusetts, Us

• Independently designed, performed the experiments and drive the oncology drug discovery project of a seed stage start-up company.• Spearheaded the development and standardization of advanced bioassay protocols.• Involved in streamlining the reagent ordering and tracking system.• Managed vendors, and trained lab personnel.The position was impacted by layoff.

Houston, Texas, Us

• Led the project to study the role of chromatin remodeling factor MOF in replication stress response which resulted in a co-corresponding author paper in Molecular and Cellular Biology, 2018. • Published 7 papers in highly reputed scientific journals.• Efficiently collaborated with the team members on different oncology research projects to enhance lab productivity. • Managed external collaborations, reviewed manuscripts and grant proposals.

Los Angeles, Ca, Us

• Extensively characterized the novel protein interactome of the Potassium Channel Tetramerization Domain (KCTD) protein family, which is an adapter molecule for Cullin-3 ubiquitin ligase using mass spectrometry and cellular assays. • Generated stable human cell lines of all 24 KCTD genes in Tetracycline-inducible Flip-in cells. • Functionally characterized the interaction of KCTD7 with PLK1 using immunoprecipitation and cell based assays.

Bethesda, Md, Us

• Published 12 papers on understanding the mechanism of RECQL4/RecQ helicases in DNA damage response.• Won 2 awards for my scientific accomplishment.• First time showed the mechanistic insight of the involvement of human RECQL4 in the Non-Homologous End-Joining (NHEJ) pathway of the DNA repair.• First time showed that the two RECQ helicases, RECQL4 and BLM cooperated physically and functionally to preserve genome integrity.• I was involved in collaborative projects to show for the first time that RECQL4 co-localizes at mitochondria and telomeres and helps in preserving genome stability. • Reviewed manuscripts submitted to reputed journals.• Worked in a collaborative project to successfully develop a novel small molecule inhibitor of BLM helicases (ML216) and helped develop cellular assays to test the efficacy of BLM inhibitors. • Executed extensive biochemical and cell biology techniques including confocal microscopy, live cell imaging, lentiviruses to generate shRNA mediated RECQL4 knockdown cell line, immunostaining, cell toxicity/proliferation assays, helicase and ATPase assays for various projects.

Ph. D., Cell/Cellular And Molecular Biology

M. Sc., Botany With Specialization In Microbial Genetics And Biotechnology.